简介:摘要目的探讨抗栓治疗与CMBs及缺血性脑卒中后脑出血转化(HT)的关系.方法选择127例急性缺血性脑卒中患者,入院3天内均行SWI序列检查,将患者分为CMBs阳性组和阴性组,记录CMBs发生例数、病灶部位、数目,记录患者的性别及年龄、病史及口服抗栓药物情况.所有患者入院后根据个体化原则予以抗血小板或抗凝治疗.治疗后2周复查SWI及CT.观察两组患者CMBs的总数、部位有无变化,有无HT.结果抗栓治疗与CMBs的发生无明显相关(P>0.05),合并CMBs的抗血小板治疗患者(10.4%)与抗凝治疗患者(14.3%)相比差异无显著性(χ2=0.324,P=0.569).抗栓治疗2周后CMBs阳性组的CMB部位、总数与入院时比较差异无统计学意义(P>0.05),CMBs阴性组未发现新的CMBs.CMBs阳性组发生HT3例(8.82%),CMBs阳性组发生HT8例(8.60%),两组比较差异无统计学意义(χ2=0.002,P=0.969).结论抗栓治疗与CMBs的发生及HT无关.关键词脑微出血;缺血性脑卒中;出血转化;抗栓治疗AbstractObjectivTostudytherelationshipabouttheantithrombotictherapywithcerebralmicrobleedsandpost-ischemicstrokehemorrhagictransforGmation(HT).MethodsToselect127casesofacuteischemicstrokepatients,SWIsequencewasperformedwithin3daysafteradmission,thepatientsweredividedintoCMBspositivegroupandnegativegroup.ThenumberofCMBs,thelocationandnumberoflesionswererecorded.Thesexandageofpatientsandthehistoryofthepatientsandtheoraldrugresistancewererecorded.Afteradmission,allpatientsweretreatedwithantiplateletoranticoagulanttherapyaccordingtotheprincipleofindividualization.2weeksaftertreatment,SWIandCTwerereviewed.ThetotalnumberandlocationofCMBsandwhetherornotHTinthetwogroupswereobserved.ResultsAntithrombotictherapyandtheincidenceofCMBShadnosignificantlycorrelated(P>0.05).Therewasnosignificantdifferenceintheantiplatelettherapypatients(10.4%)andanticoagulationtherapypatients(14.3%)(χ2=0.324,P=0.569).TherewasnosignificantdifferenceinthenumGberofCMBsitesandthetotalnumberofCMBspositivegroup(P>0.05)after2weeksoftreatment,andthenewCMBswasnotfoundinCMBsnegativegroup.IntheCMBSpositivegroup,3caseswereHT(8.82%),IntheCMBSpositivegroup,8caseswereoccurred(8.60%).ThedifferencebetweenthetwogroupswasnostatKisetyicwalorsdigsnificance(χ2=0.002,P=0.969).ConclusionTheantithrombotictherapyisnotassociatedwiththeoccurrenceofCMBsandHT.Cerebralmicrobleeds;Ischemicstroke;Hemorrhagictransformation;Antithrombotictherapy中图分类号R743.3文献标识码B文章编号1001-5302(2015)09-0658-02
简介:摘要目的分析培美曲塞二钠及顺铂治疗复发转移性乳腺癌的临床疗效。方法依据纳入/排除标准共选取2012年6月--2014年3月收治的复发转移性乳腺癌患者64例,应用培美曲塞二钠联顺铂治疗,观察并分析其效果。结果治疗后复发转移性乳腺癌患者的用药完全缓解4例(6.25%),部分缓解20例(31.25%),稳定20例(31.25%),进展20例(31.25%),有效率及获益率分别为37.50%及68.75%。无死亡病例。其主要的不良反应为疲乏及外周血白细胞减少,及时进行应对治疗后,不良反应得到较好控制,未影响用药疗效及治疗活动开展。在治疗后患者的CA153及KPS评分值均发生变化,差异具有统计学意义(P<0.05)。结论培美曲塞联合顺铂治疗方案用于复发转移性乳腺癌患者,可明显降低相关抗原指标,提高患者生存质量,不良反应较轻,安全性良好,可在临床推广使用。